Related Experiment Video
Updated: Nov 20, 2025
11:27
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
2.3K
Release characteristics of gliclazide in a matrix system
Mehmet Melih Tatlisoz1, Esra Demirturk2, Cetin Canpolat1
1Biomedical Engineering Department, Faculty of Engineering, Cukurova University, 01250 Adana, Turkey.
In Silico Pharmacology
|January 25, 2021
Summary
This study models gliclazide release from polymeric matrices using the finite element method, finding matrix porosity significantly impacts dissolution rate for controlled drug delivery.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
- Computational Modeling
Background:
- Controlled drug release systems aim to optimize therapeutic efficacy and patient compliance.
- Polymeric matrix systems are widely employed for sustained and controlled delivery of active pharmaceutical ingredients.
- Gliclazide is an oral hypoglycemic agent used in managing type 2 diabetes mellitus.
Purpose of the Study:
- To experimentally and numerically investigate the release characteristics of gliclazide from a polymeric matrix.
- To develop and validate a finite element method (FEM) code for predicting gliclazide release kinetics.
- To identify key parameters influencing drug dissolution rate in a controlled release system.
Main Methods:
- Experimental dissolution studies of gliclazide in a polymeric matrix.
- Development of a numerical code based on the finite element method to simulate drug release.
- Systematic variation of parameters including structure factor, slab size, and shape.
- Evaluation of solid drug reduction during the dissolution process.
Main Results:
- The developed FEM code accurately predicts gliclazide release behavior, showing good agreement with experimental data.
- Matrix porosity was identified as the most critical factor affecting the drug dissolution rate.
- Reducing tablet diameter and using cylindrical slab geometry were found to accelerate drug dissolution.
Conclusions:
- The developed numerical code provides an accurate model for predicting controlled gliclazide release from polymeric matrices.
- Matrix porosity is a key design parameter for controlling the dissolution rate of gliclazide.
- Geometric factors of the drug delivery system can be optimized to modulate drug release speed.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
407
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
407
01:24Glucagon-like Receptor Agonists
580
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
580
01:23Dipeptidyl Peptidase 4 Inhibitors
360
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
360
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
447
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
447
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
394
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
394
01:27Insulin Formulations: Types and Delivery
401
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
401